A novel ARHGAP family gene signature for survival prediction in glioma patients
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18555 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Jin Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, J…. Hauptthemen laut MEDLINE: Glioma, GTPase-Activating Proteins, Gene Expression Regulation, Neoplastic, Nomograms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Scientific research project of Wuxi health commission, The Youth project of Wuxi commission of Health.
Abstract (Originalsprache)
ARHGAP family genes are often used as glioma oncogenic factors, and their mechanism of action remains unexplained. Our research entailed a thorough examination of the immune microenvironment and enrichment pathways across various glioma subtypes. A distinctive 6‐gene signature was developed employing the CGGA cohort, leading to insights into the disparities in clinical characteristics, mutation patterns, and immune cell infiltration among distinct risk categories. Additionally, a unique nomogram was established, grounded on ARHGAPs, with DCA curves illustrating the model's prospective clinical utility in guiding therapeutic strategies. Emphasizing the role of ARHGAP30, integral to our model, its impact on glioma severity and the credibility of our risk assessment model were substantiated through RT‐qPCR, Western blot analysis, and cellular functional assays. We identified 6 ARHGAP family genes associated with glioma prognosis. Analysis using the Kaplan–Meier method indicated a correlation between elevated risk levels and adverse outcomes in glioma patients. The risk score, linked with tumour staging and IDH mutation status, emerged as an independent factor predicting prognosis. Patients in the high‐risk category exhibited increased immune cell infiltration, enhanced tumour mutational burden, more pronounced expression of immune checkpoint genes, and a better response to ICB therapy. A nomogram, integrating the risk score with the pathological features of glioma patients, was developed. DCA analysis and cellular studies confirmed the model's potential to improve clinical treatment outcomes for patients. A novel ARHGAP family gene signature reveals the prognosis of glioma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, China.
ORCID-Profile: Jin Huang
Förderung
- National Natural Science Foundation of China
- Scientific research project of Wuxi health commission
- The Youth project of Wuxi commission of Health
- Wuxi Taihu Lake Talent Plan, Supports for Leading Talents in Medical and Health Profession
- The Basic Research Project of Wuxi Science and Technology Bureau
Zitieren
APA
Huang, J., Wang, G., Zhang, J., Liu, Y., Shen, Y., Chen, G., Ji, W., & Shao, J. (2024). A novel ARHGAP family gene signature for survival prediction in glioma patients. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18555
Vancouver
Huang J, Wang G, Zhang J, Liu Y, Shen Y, Chen G, et al. A novel ARHGAP family gene signature for survival prediction in glioma patients. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18555
BibTeX
@article{Huang2024,
author = {Huang, Jin and Wang, Gaosong and Zhang, Jiahao and Liu, Yuankun and Shen, Yifan and Chen, Gengjing and Ji, Wei and Shao, Junfei},
title = {A novel ARHGAP family gene signature for survival prediction in glioma patients},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18555}
}
EUVIMED